Wed, Dec 24, 2014, 9:30 PM EST - U.S. Markets closed early today


% | $
Quotes you view appear here for quick access.

Seattle Genetics Inc. Message Board

ricardouno 8 posts  |  Last Activity: Dec 10, 2014 5:05 PM Member since: Jun 5, 1998
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Google: Brentuximab Vedotin Leah Lawrence

    Interesting quote in the report:

    “Once this is published, in this particular patient population … I do believe that it will become standard treatment,” Moskowitz during his oral abstract presentation.

    Good luck to all !


  • Reply to

    The piece of Data

    by atpl1959 Dec 8, 2014 1:11 PM
    ricardouno ricardouno Dec 8, 2014 2:39 PM Flag

    atpl1959 : That's an interest thought.........because............

    In patients who previously responded to treatment with ADCETRIS, then discontinued treatment and subsequently had disease progression or relapse........there are data that suggest Adcetris ITSELF may be a reasonable retreatment option:

    "At the 2012 ASCO Annual Meeting, retreatment data from the phase II trial were reported from 23 patients, including one patient who was treated twice. Patients had received a median of four prior systemic therapies, including ADCETRIS. Of 23 evaluable patients, 70 percent (16 of 23) achieved an objective response after retreatment with ADCETRIS, including nine complete remissions and seven partial remissions. Median duration of retreatment objective response was 8.8 months. Among retreated HL patients, nine of 16 (56 percent) achieved an objective response. Among retreated sALCL patients, seven of eight (88 percent) achieved an objective response. The most common adverse events were peripheral neuropathy (46 percent), nausea (42 percent), fatigue (38 percent), diarrhea (33 percent) and fever (29 percent). "

  • Reply to


    by llabtechtwo Dec 8, 2014 12:01 PM
    ricardouno ricardouno Dec 8, 2014 12:18 PM Flag

    Yes, quite IMPRESSIVE data released today. I am not so sure the market is truly "worried".......Wall Street, day to day, is a fickle thing subject to manipulation. Hard to gauge just what is at work here. Good luck to all. Ricardo
    -Long-Term Data from Phase 1 Trial of ADCETRIS Combined with AVD in Frontline Hodgkin Lymphoma Demonstrate 100 Percent Three-Year Overall Survival Rate and 92 Percent Three-Year Failure-Free Survival Rate; Data Provide Continued Strong Support for ECHELON-1 Trial-

    -ADCETRIS in Combination with Bendamustine in Relapsed or Refractory Hodgkin Lymphoma as Second-line Therapy Shows Objective Response Rate of 96 Percent and Complete Remission Rate of 83 Percent-

    -Interim Data from ADCETRIS Phase 2 Clinical Trial in Previously Untreated Hodgkin Lymphoma Patients Age 60 or Older Demonstrate 93 Percent Objective Response Rate-

    -Data from Multiple Trials Support Goal to Establish ADCETRIS as Foundation of Therapy in Frontline and Salvage Hodgkin Lymphoma and Other CD30-Positive Malignancies-

  • HAMPTON, N.J., Dec. 4, 2014 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (CLDX) today announced that it has initiated an open-label Phase 2 study of glembatumumab vedotin (CDX-011) in patients with unresectable Stage III or IV melanoma. Glembatumumab vedotin is a fully-human monoclonal antibody-drug conjugate (ADC) that targets glycoprotein NMB (gpNMB), a protein overexpressed by multiple tumor types, including metastatic melanoma where approximately 85% of patients overexpress the marker. Overexpression of gpNMB has been shown to promote the invasion and metastasis of cancer and has been associated with poor clinical outcome. The study is expected to include up to 10 sites in the United States and will enroll approximately 60 patients. Glembatumumab vedotin was previously evaluated in a Phase 1/2 study in patients with unresectable stage III or stage IV melanoma, a Phase 1/2 study in advanced breast cancer, a Phase 2 study in advanced breast cancer (the EMERGE study) and is currently being evaluated in patients with metastatic triple negative breast cancers that overexpress gpNMB in the METRIC Study.

  • Reply to

    SGN CD 33A

    by atpl1959 Nov 6, 2014 9:31 AM
    ricardouno ricardouno Nov 6, 2014 10:37 AM Flag

    I was struck by the remarkable dose response curve in the previously presented pre-clinical data. There, at a certain point, as the higher doses were achieved, the response ( blast cell elimination ) went vertical to essentially 100%.

    Although it's difficult to extrapolate directly to the clinic, I would not be surprised if the clinical response rate is eventually shown to be highly dose dependent. Combination or sequential therapy with low dose chemo agents to concomitantly or first reduce the blast load might then prove sensible as an extension of what was noted pre-clinically.

    All the best,


  • ricardouno by ricardouno Nov 4, 2014 5:23 PM Flag

    Does anyone think there is a possibility of a special year end distribution....or am I just dreaming?



  • Reply to

    Tick tock to earnings and CC

    by redhot47fla Oct 30, 2014 4:03 PM
    ricardouno ricardouno Oct 30, 2014 5:51 PM Flag

    I thought this was an excellent call.....perhaps the best ever in fact. Almost all the answers were addressed as best as realistically possible or expected and there was no outrageous evasiveness at all. Lots of very specific questions were met with good answers from the team assembled. Finances, sales, collaborations, research, trials, pipeline all seem to moving in the right direction. Quite a bit of energy and enthusiasm expressed.....and they actually made it seem appropriately justified. Now if we just didn't have the tabloid stuff.......................

    Good luck to all!


  • ricardouno by ricardouno Sep 29, 2014 7:38 AM Flag

    Notable OS separation between the two arms might be difficult to show or may take long to reveal itself if the study drug ( Adcetris ) is used on most in the placebo arm after progression.....especially if the drug is just that effective at almost any stage.

    Opinions welcome.


31.10-0.14(-0.45%)Dec 24 12:59 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.